Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella

This article was originally published in The Gray Sheet

Executive Summary

The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.

Advertisement

Related Content

Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
FDA Sets PMA Standard For AEDs, Giving Marketed Devices Time To Comply
FDA Seeks PMA Requirements For More Pre-Amendment Devices
Abiomed Makes Its Case For Impella In High-Risk Angioplasty Cases
FDA Orders Firms To Submit Data For 25 Pre-Amendment Device Types

Topics

Advertisement
UsernamePublicRestriction

Register

MT034625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel